Desonide: A review of formulatins, efficacy and safety

Expert Opinion on Investigational Drugs

Volumn 17, Issue 7, 2008, Pages 1097-1104

  Kahanek, N R ^a   Gelbard, Christina M ^a   Hebert, A A ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Acne; Adverse events; Atopic dermatitis; Contact dermatitis; Desonide; Efficacy; Mechanism of action; Safety; Topical corticosteroids

Indexed keywords

BETAMETHASONE DIPROPIONATE; CITRIC ACID; CORTICOSTEROID; DESOCORT; DESONATE; DESONIDE; DODECYL SULFATE SODIUM; EDETATE SODIUM; GALLIC ACID PROPYL ESTER; GLUCOCORTICOID; GLYCEROL STEARATE; HEXADECANOL; HYDROCORTISONE; LOKARA; METHYL PARABEN; MINERAL OIL; MYRISTIC ACID ISOPROPYL ESTER; OCTADECANOL; PALMITIC ACID ISOPROPYL ESTER; POLYETHYLENE; POLYSORBATE 60; PROPOLIS; PROPYL PARABEN; PROPYLENE GLYCOL; SODIUM HYDROXIDE; SORBATE POTASSIUM; SORBIC ACID; SORBITAN STEARATE; STEARIC ACID; UNINDEXED DRUG; VERDESO; WATER; WAX; WHITE PETROLATUM;

ACNE; ANTIINFLAMMATORY ACTIVITY; APPLICATION SITE BURNING; APPLICATION SITE PRURITUS; APPLICATION SITE RASH; ATOPIC DERMATITIS; BLEACHING; BLISTER; CATARACT; CLINICAL TRIAL; CONTACT DERMATITIS; CREAM; CUSHING SYNDROME; DERMATITIS; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; DRY SKIN; ECZEMA; ENDOCRINE DISEASE; ERYTHEMA; EYE IRRITATION; EYE SWELLING; FACE EDEMA; FOAM; FOLLICULITIS; GEL; GROWTH RETARDATION; HUMAN; HYPOPIGMENTATION; INTRACRANIAL HYPERTENSION; IRITIS; LOTION; NONHUMAN; OINTMENT; OSTEOPOROSIS; PERIORAL DERMATITIS; PHARMACODYNAMICS; PSORIASIS; REVIEW; SEBORRHEIC DERMATITIS; SECONDARY INFECTION; SIDE EFFECT; SKIN ABRASION; SKIN ATROPHY; SKIN BURNING SENSATION; SKIN INDURATION; SKIN IRRITATION; SKIN PRURITUS; SKIN SCAR; SKIN SENSITIVITY; SKIN SWELLING; SKIN TINGLING; SLEEP DISORDER; STRIA; SWEAT GLAND DISEASE; TELANGIECTASIA; UPREGULATION; VASOCONSTRICTION; CHEMISTRY; DRUG DOSAGE FORM;

CHEMISTRY, PHARMACEUTICAL; DESONIDE; DOSAGE FORMS; HUMANS;

EID: 48249156924     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.17.7.1097     Document Type: Review

References (26)

1. Stahn C, Lowenberg M, Hommes DW, Buttgereit F. Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists. Mol Cell Endocrinol 2007;275:71-8
2. Smith EB, Gregory JF, Bartruff JK. Desonide, a potent nonfluorinated topical steroid, vasoconstriction assay and clinical trial. South Med J 1973;66:325-9
3. Eichenfield LF, Basu S, Calvarese B, Trancik RJ. Effect of desonide hydrogel 0.05% on the hypothalamic-pituitary-adrenal axis in pediatric subjects with moderate to severe atopic dermatitis. Pediatr Dermatol 2007;24:289-95
4. Wolverton S. Comprehensive dermatologic drug therapy. 2nd edtion. Philadelphia: Elsevier; 2007
5. Foti C, Cassano N, Vena GA. Evaluation of cross-reactivity between budesonide and desonide. Contact Dermatitis 2002;47:109-10
6. Ahluwalia A. Topical glucocorticoids and the skin. Mechanisms of action: an update. Mediators Inflamm 1998;7:183-93
7. SkinMedica. Desonate™ (desonide) Gel 0.05% package insert, 2006. Available from: www.fda.gov/cder/foi/label/2006/0218441bl.pdf [last accessed 28 May, 2008]
8. Hebert AA, Cook-Bolden FE, Basu S, et al. Safety and efficacy of desonide hydrogel 0.05% in pediatric subjects with atopic dermatitis. J Drugs Dermatol 2007;6:175-81
9. Thalen A, Brattsand R, Andersson PH. Development of glucocorticosteroids with enhanced ratio between topical and systemic effects. Acta Derm Venereol Suppl (Stockh) 1989;151:11-9; discussion 47-52
10. Verdeso. desonide) Foam, 0.05% package insert, 2006. Available from: www.verdeso.com/pdf/PI.pdf [last accessed 29 May, 2008]
11. Galderma. 2007. Available from: www.galderma.ca/en/prod_sterc.cfm [last accessed 31 March, 2008]
12. Desowen. Website, 2007. Available from: www.rxlist.com/cgi/generic/ desonide.htm [last accessed 29 May, 2008]
13. Fougera. Desonide loiton 0.05% package insert, 2007. Available from: www.fougera.com/products/documents/1170.PI.pdf [last accessed 29 May, 2008]
14. Taro. Desonide cream 0.05%, desonide ointment 0.05% package insert, 2007. Available from: www.taro.com/media/oMedia/215_6_300.pdf [last accessed 29 May, 2008]
15. LOKARA. LoKara™ Lotion (desonide lotion 0.05%) package insert, 2005. Available from: www.pharmaderm.com/physician_info/lokara/ lokara_lotion.html [last accessed 29 May, 2008]
16. Jorizzo J, Levy M, Lucky A, et al. Multicenter trial for long-term safety and efficacy comparison of 0.05% desonide and 1% hydrocortisone ointments in the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 1995;33:74-7
17. Bhankharia DA, Sanjana PH. Efficacy of desonide 0.05% cream and lotion in steroid-responsive dermatoses in Indian patients: a post-marketing surveillance study. Indian J Dermatol Venereol Leprol 2004;70:288-91
18. Freeman S, Howard A, Foley P, et al. Efficacy, cutaneous tolerance and cosmetic acceptability of desonide 0.05% lotion (DesOwen) versus vehicle in the short-term treatment of facial atopic or seborrhoeic dermatitis. Australas J Dermatol 2002;43:186-9
19. Lebrun-Vignes B, Legrain V, Amoric J, Taieb A. Comparative study of efficacy and effect on plasma cortisol levels of micronised desonide cream 0.1 p. 100 versus betamethasone dipropionate cream 0.05 p. 100 in the treatment of childhood atopic dermatitis. Ann Dermatol Venereol 2000;127:590-5
20. Sturtz RP, Rau RC. Contact dermatitis to desonide. Arch Dermatol 1983;119:1023
21. Hernandez N, Assier-Bonnet H, Terki N, Revuz J. Allergic contact dermatitis from propyl gallate in desonide cream (Locapred). Contact Dermatitis 1997;36:111
22. Rivara G, Tomb RR, Foussereau J. Allergic contact dermatitis from topical corticosteroids. Contact Dermatitis 1989;21:83-91
23. Wong VK, Fuchs B, Lebwohl M. Overview on desonide 0.05%: a clinical safety profile. J Drugs Dermatol 2004;3:393-7
24. Brodell RT, O'Brien MJ Jr. Topical corticosteroid-induced acne. Three treatment strategies to break the 'addiction' cycle. Postgrad Med 1999;106:225-6, 229
25. Lucky AW, Grote GD, Williams JL, et al. Effect of desonide ointment, 0.05%, on the hypothalamic-pituitary-adrenal axis of children with atopic dermatitis. Cutis 1997;59:151-3
26. Tarayre JP, Aliaga M, Barbara M, et al. Comparison of the cutaneous/ systemic antiinflammatory activity ratios for desonide and hydrocortisone in various experimental models. Arzneimittelforschung 1988;38:542-5